Rezolute Inc. (NASDAQ:RZLT)报告Q损失为4.4美元/share,损失估计数为1.4美元/14美元,而7名分析家将其定为“买” Rezolute Inc. (NASDAQ:RZLT) reported a Q loss of $0.44/share, missing estimates by $0.14, while 7 analysts rated it a "buy"
一家临床阶段生物制药公司Rezulute Inc.(NASDAQ:RZLT)报告,每季度每股损失0.44美元,预期损失1.4美元。 Rezolute Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical firm, reported a quarterly loss of $0.44 per share, missing expectations by $0.14. 尽管如此,7名分析家将库存评为“购买”,平均价格目标是11.57美元。 Despite this, seven analysts rated the stock as a "buy," with an average price target of $11.57. 该公司的主要候选药物RZ358正在进行2b期先天性高胰岛素症试验. The company’s lead candidate, RZ358, is in Phase 2b trials for congenital hyperinsulinism. Rezolute的股票以5.08美元开放,市场上限为2.0389亿美元。 Rezolute's stock opened at $5.08 and has a market cap of $203.89 million.